Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Vitrakvi |
|---|---|
| Manufacturer | BayerHealthCare Pharmaceuticals Inc |
| Prescription required | Yes |
Vitrakvi Oral Solution 20mg/ml 100ml(larotrectinib)
larotrectinib
Description
Vitrakvi Oral Solution 20mg/ml 100ml(larotrectinib) is a medicine catalog record in the MediPriceHub database. Active ingredient: larotrectinib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: BayerHealthCare Pharmaceuticals Inc. Therapeutic category: Medicine Library > Oncology Medicines > Brain Cancer Medicines. Pack information: 200 / 100. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ].How to Use
Use larotrectinib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: larotrectinib. Pack size: 200 / 100. Pack unit: bottle. Manufacturer: BayerHealthCare Pharmaceuticals Inc. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Brain Cancer Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Not limited to cancer types! Bayer's "broad-spectrum" targeted anticancer drug Vitrakvi treats TRK fusion cancer: the total remission rate is as high as 71%, and the quality of life is improved! Vitrakvi is an oral TRK inhibitor, specifically used to treat children and adults with advanced or metastatic solid tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusion in the tumor.At present, Vitrakvi has been approved in many countries and regions around the world, including the United States, Brazil, Canada, and EU countries. PRINCIPAL DISPLAY PANEL Package Label - Carton - 20mg/mL -100mL Oral Solution (larotrectinib) oral solution 20 mg/mL larotrectinib sulfate). 100mL oral solution oral useDiese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.